First I never said the stock would be bought out. Second your are the one attacking me saying, "Keep Dreaming". All I said was I hope this surpasses $3 by the end of the week. I have done some DD and honestly believe the glaucoma trial will meet the primary and secondary endpoints. I also said if it doesn't I am ok with that. So to call me Mr. Hot-Head please just look at what you posted. I have been civil.
I am not worried that we are not sitting at $3/share. After DD I think the glaucoma trial will be positive. That should push this stock to $4-$5/share. If I am wrong that's ok too. The HCC results and NASH is where its at. Positive HCC results will catapult this stock to new levels. So before I wake up from the apparent dream I am in take note that your an #$%$ ........WHOLE!!!!!
I would really like the results of the HCC trial to come out first then glaucoma. That would make this stock jump quick.
It has been over 3 weeks since any type of PR. The company has been very quiet. I know that is great for the HCC trial however how does that translate to the Glaucoma trial. Could it be similar to Psoriasis that it didn't meet meet the primary endpoint point however the longer the study went the better the results.
Ok so I took a lot of time to read the CF101 Dry Eye trial that failed. I don't see a phase 1 Glaucoma trial to read results. The original trial phase 2 Glaucoma trial was supposed to have results by the end of 2015. Now they are saying by the end of 1H of 2016. What are the chances introcular pressure meets the primary endpoint. Management does not provide us with a lot information and I have too much money tied up in this company.
Am I wrong about the overall share count being 13-14 million? I thought it was 11 million. Are they diluting? If so that is not good before resuits because if the results are bad this tanks and they have a few extra million to work with.
It looks like the company will not release any news until after the General Meeting on May 30th. It would be nice to have them release the HCC news as the first treated patient was 12/2014 so its been 17 months. In the first trial the OS was 8.1 months. They did mention on Clinical Trials dot gov that they will continue to watch all the subjects until they reach 75 deaths.
So in the last hour more than half the shares traded were bought and sold. This stock starts out VERY SLOW then picks up in the afternoon with it usually ending in red or green by a penny or two.
Sentiment: Strong Buy
OK, so I read the results of Phase 1/2 for HCC. For Child Pugh B the median survival rate was 8.1 months while placebo was 4 months. Great results considering you live twice as long. The phase 2 HCC trial started in 09/2014. One would think that since the O/S is not long that results should be released soon. We are 18 months into this trial.
Another non-event day. I have been a part of several boards over the years and never have I been a part of one where no one talks. Stocks I have been a part of are ACAD, INO, CLSN, OPK, and of course this one.